15

A share anti epidemic: jialinjie was expropriated and Shangrong medical was selected as a designated enterprise

category:Finance
 A share anti epidemic: jialinjie was expropriated and Shangrong medical was selected as a designated enterprise


Lepu medical (300003. SZ) also said in the evening of February 6 that on that day, the company received a notice from its subsidiary, Beijing epyi Medical Testing Center Co., Ltd. (hereinafter referred to as the epyi medical testing center), according to the new coronary disease on medical institutions and third-party testing institutions jointly issued by Beijing Municipal Commission of health, Beijing Municipal Medical Security Bureau and Beijing Municipal Bureau of finance The third batch of new coronavirus nucleic acid testing units in Beijing were selected by epeyi medical testing center. According to the notice, the results of etiological tests issued by the municipal and district centers for Disease Control and prevention, hospitals and third-party testing institutions that are confirmed to meet the requirements can be used as the basis for diagnosis. Each medical institution may select a qualified third-party detection institution to detect the viral nucleic acid of pneumonia cases infected with new coronavirus in combination with the actual work.

According to the data, as a third-party medical testing institution, epeyi medical testing center is specialized in biochemical, immune, molecular diagnosis, microorganism, pathology, genetic metabolism, blood disease special examination and other services. Its business area covers the whole country. Specialized laboratories provide accurate, efficient and comprehensive medical diagnosis outsourcing services for medical and health institutions at all levels. At present, the equipment used in the new coronavirus nucleic acid detection by epeyi medical testing center is the full-automatic nucleic acid extractor produced by Yantai adekang Biotechnology Co., Ltd., a subsidiary of IVD Business Department of the company, and the full-automatic medical PCR analysis system produced by Beijing Lepu Medical Technology Co., Ltd. the above equipment cooperates with nucleic acid detection reagents to complete the detection of viral nucleic acid.

Shangrong medical (002551. SZ) issued the announcement of abnormal fluctuation of stock trading on the evening of February 6, which revealed that in order to solve the problem of serious shortage of production and supply of medical protective clothing at present, Hefei pulde medical supplies Co., Ltd., the holding subsidiary of the company (hereinafter referred to as pulde medical, the company holds 55% of the shares of the company), has been dealt with by the State Council in response to the pneumonia caused by the new coronavirus infection The material support group of the joint prevention and control mechanism was determined as the first batch of designated enterprises of emergency medical material protective clothing.

It is reported that the main products of pulde medical are medical nano antibacterial and antiviral composite materials, disposable surgical bags, disposable surgical gowns and protective clothing and other medical protective products. Pulde medical is currently a large-scale enterprise that produces, develops and sells disposable non-woven medical products and medical non-woven fabric products in China. At the same time, pulde medical has passed ISO13485, CE and FDA certification We have long-term cooperation with MEDLINE, DuPont, 3M, Kimberley and other well-known international medical consumables enterprises. Pulde medical has an annual output of 70 million disposable surgical gowns, 10 million protective clothing, 1500 standard containers for disposable surgical bags, surgical shop sheets and other products, and 8300 tons of nano non-woven raw materials.

In addition, Xuebijing injection produced by HongRi Pharmaceutical Co., Ltd. (300026. SZ) is listed in other treatment measures for severe and critical cases and recommended medication in clinical treatment period of traditional Chinese medicine in the new diagnosis and treatment scheme for pneumonia caused by coronavirus infection (trial version 5) jointly issued by the National Health Commission and the State Administration of traditional Chinese medicine; Yiling Pharmaceutical Co., Ltd. (002603. SZ) The patent Lianhua Qingwen capsule and its wholly-owned subsidiary Beijing Yiling Pharmaceutical Co., Ltd. are listed as the recommended drugs for the observation period of traditional Chinese medicine treatment.

It is worth mentioning that in addition to Lepu medical, there are many companies that have developed test reagents.

Kaipu biological (300639. SZ) said on February 3 that it had completed the registration sampling of the test kit and applied to the drug regulatory department for emergency approval of medical devices.

Dean diagnostics (300244. SZ) announced on February 3 that it has completed the kit registration test in Zhejiang medical device inspection and Research Institute. Meikang Biology (300439. SZ) announced on February 3 that it also submitted samples and relevant information to the State Drug Administration for registration. In addition, Wanfu Biology (300482. SZ), toujing life (300642. SZ), Xilong Science (002584. SZ), shuoshi Biology (688399. SH) and so on are involved in the development of detection reagents. As for Zhifei Biology (300122. SZ), its wholly-owned subsidiary and Institute of Microbiology of Chinese Academy of Sciences signed a framework agreement of cooperation intention on January 29 to develop 2019 ncov recombinant protein subunit vaccine. Source: editor in charge of interface news: Zhang Meiyu nf2100

Dean diagnostics (300244. SZ) announced on February 3 that it has completed the kit registration test in Zhejiang medical device inspection and Research Institute.

Meikang Biology (300439. SZ) announced on February 3 that it also submitted samples and relevant information to the State Drug Administration for registration.

In addition, Wanfu Biology (300482. SZ), toujing life (300642. SZ), Xilong Science (002584. SZ), shuoshi Biology (688399. SH) and so on are involved in the development of detection reagents.

As for Zhifei Biology (300122. SZ), its wholly-owned subsidiary and Institute of Microbiology of Chinese Academy of Sciences signed a framework agreement of cooperation intention on January 29 to develop 2019 ncov recombinant protein subunit vaccine.